Pharma Deals Review, Vol 2009, No 8 (2009)

Font Size:  Small  Medium  Large

CombinatoRx and Clinical Data Collaborate on Adenosine Agonist for Cancer

Taskin Ahmed

Abstract


Clinical Data and CombinatoRx sign a licensing agreement valued at up to US$252 M for the development of a novel cancer drug to treat multiple myeloma and other B-cell cancers. The deal centres on Clinical Data’s adenosine A2A agonist, ATL313.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.